Processing

Please wait...

Settings

Settings

Goto Application

1. WO2009106980 - INDAZOLE DERIVATIVES

Publication Number WO/2009/106980
Publication Date 03.09.2009
International Application No. PCT/IB2009/000409
International Filing Date 26.02.2009
IPC
A61P 25/04 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
04Centrally acting analgesics, e.g. opioids
A61K 31/416 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
4151,2-Diazoles
416condensed with carbocyclic ring systems, e.g. indazole
C07D 231/56 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
231Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
54condensed with carbocyclic rings or ring systems
56Benzopyrazoles; Hydrogenated benzopyrazoles
C07D 401/12 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
C07D 403/12 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
C07D 405/06 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
405Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
02containing two hetero rings
06linked by a carbon chain containing only aliphatic carbon atoms
CPC
A61K 31/416
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
4151,2-Diazoles
416condensed with carbocyclic ring systems, e.g. indazole
A61K 31/4162
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
4151,2-Diazoles
4162condensed with heterocyclic ring systems
C07D 231/56
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
231Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
54condensed with carbocyclic rings or ring-systems
56Benzopyrazoles; Hydrogenated benzopyrazoles
C07D 401/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
C07D 403/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
C07D 405/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
405Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
02containing two hetero rings
06linked by a carbon chain containing only aliphatic carbon atoms
Applicants
  • PFIZER INC. [US]/[US] (AllExceptUS)
  • BUCHLER, Ingrid, Price [US]/[US] (UsOnly)
  • HAYES, Michael, Joseph [US]/[US] (UsOnly)
  • HEGDE, Shridhar, Gajanan [US]/[US] (UsOnly)
  • HOCKERMAN, Susan, Landis [US]/[US] (UsOnly)
  • JONES, Darin, Eugene [US]/[US] (UsOnly)
  • KORTUM, Steven, Wade [US]/[US] (UsOnly)
  • RICO, Joseph, Gerace [US]/[US] (UsOnly)
  • TENBRINK, Ruth, Elizabeth [US]/[US] (UsOnly)
  • WU, Kun Ken [CA]/[US] (UsOnly)
Inventors
  • BUCHLER, Ingrid, Price
  • HAYES, Michael, Joseph
  • HEGDE, Shridhar, Gajanan
  • HOCKERMAN, Susan, Landis
  • JONES, Darin, Eugene
  • KORTUM, Steven, Wade
  • RICO, Joseph, Gerace
  • TENBRINK, Ruth, Elizabeth
  • WU, Kun Ken
Agents
  • BENSON, Gregg, C.
Priority Data
61/032,66729.02.2008US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) INDAZOLE DERIVATIVES
(FR) DÉRIVÉS D'INDAZOLE
Abstract
(EN)
This invention relates to compounds, pharmaceutical compositions and methods for the treatment of a condition mediated by CB1 receptor activity in a mammalian subject including a human, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of the compound of Formula (I): wherein R1, R2 and R3 are as defined in this specification.
(FR)
Cette invention concerne des composés, des compositions pharmaceutiques et des méthodes de traitement d'une pathologie induite par l'activité du récepteur CB1 chez un mammifère, notamment chez l'homme. Ces méthodes consistent à administrer à un mammifère nécessitant un tel traitement une quantité thérapeutiquement efficace du composé de formule (I), dans laquelle R1, R2 et R3 sont tels que définis dans la description.
Latest bibliographic data on file with the International Bureau